10-Q: Spruce Biosciences Q3 2025: Strategic Pivot & $50M Boost

Spruce Biosciences reports Q3 2025 financial results, highlighting a strategic pivot to TA-ERT for Sanfilippo Syndrome Type B, FDA Breakthrough Therapy Designation, and a recent $50 million private placement to address liquidity concerns.

Summary

• Net loss for the nine months ended September 30, 2025, was $24.3 million, an improvement from $29.5 million in the prior year.
• Cash and cash equivalents stood at $10.7 million as of September 30, 2025, down from $38.8 million at December 31, 2024.
• Subsequent to the quarter, the company secured approximately $50.0 million in gross proceeds from a private placement financing in October 2025.
• The company terminated its Term Loan with Silicon Valley Bank on November 7, 2025, by prepaying $0.4 million principal and $0.3 million in fees.
• A 1-for-75 reverse stock split was effected on August 4, 2025, leading to relisting on Nasdaq Capital Market on September 15, 2025, after a temporary delisting.
• A workforce reduction of 55% was implemented in April 2025 to prioritize tralesinidase alfa (TA-ERT) development.
• TA-ERT for Sanfilippo Syndrome Type B received FDA Breakthrough Therapy Designation in October 2025.
• A Biologics License Application (BLA) for TA-ERT is anticipated in Q1 2026, with a potential commercial launch in late 2026.
• The company is advancing tildacerfont in a Phase 2 proof-of-concept study (TAMARIND) for Major Depressive Disorder, with topline results expected in H1 2026.
• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months following the financial statement issuance date without further financing.

Sentiment

Score: 4

Explanation: While the FDA Breakthrough Therapy Designation for TA-ERT and the recent capital raise are positive, the company's severe liquidity issues, going concern doubt, lack of revenue, and significant workforce reduction indicate a challenging financial position and high operational risk. The strategic pivot is necessary but comes after significant setbacks.

Positives

• Net loss for the nine months ended September 30, 2025, decreased to $24.3 million from $29.5 million in the prior year.
• Net cash used in operating activities decreased by $8.4 million to $26.9 million for the nine months ended September 30, 2025, compared to $35.3 million in the prior year.
• Received FDA Breakthrough Therapy Designation for tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B in October 2025.
• Successfully raised approximately $50.0 million in gross proceeds from a private placement financing in October 2025, improving liquidity.
• Successfully relisted on the Nasdaq Capital Market on September 15, 2025, following a reverse stock split and prior delisting.
• TA-ERT therapy demonstrated significant reduction of CSF HS-NRE levels to normal or near normal over five years in clinical studies, with most participants experiencing normalization within eight weeks.
• Children with established MPS IIIB treated with TA-ERT experienced stable cognitive function over time, contrasting with decline in untreated children.
• TA-ERT treatment was associated with stabilization of cortical grey matter volume (CGMV).
• TA-ERT therapy exposure for up to 7.3 years demonstrated an adequate safety profile in a serious and fatal disease with no current treatment.
• FDA confirmed CSF-HS-NRE as a biomarker reasonably likely to predict clinical benefit for accelerated approval of TA-ERT.
• FDA confirmed completed clinical and nonclinical studies of TA-ERT were sufficient for BLA submission.
• Term Loan with Silicon Valley Bank was fully prepaid and terminated in November 2025, reducing future debt obligations.

Negatives

• Incurred a net loss of $24.3 million for the nine months ended September 30, 2025, and an accumulated deficit of $274.6 million.
• Cash and cash equivalents decreased significantly to $10.7 million as of September 30, 2025, from $38.8 million at December 31, 2024.
• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months following the financial statement issuance date without additional financing beyond the recent private placement.
• Collaboration revenue was $0 for the nine months ended September 30, 2025, a significant decrease from $4.2 million in the prior year, indicating a lack of product sales revenue.
• Experienced a delisting from Nasdaq on April 29, 2025, due to failure to comply with the minimum bid price requirement, although subsequently relisted.
• A 55% workforce reduction was implemented in April 2025, incurring $0.9 million in expenses, reflecting significant operational restructuring due to financial pressures.
• The tildacerfont CAH development program was discontinued due to not meeting its primary efficacy endpoint in trials.
• The prior sponsor of TA-ERT, Allievex, discontinued clinical development due to financial constraints.
• The company has no products approved for commercial sale and has not generated any product revenue to date.
• Expected to continue to incur significant and increasing losses for the foreseeable future.

Risks

• Do not currently have sufficient working capital to fund planned operations for the next twelve months, and substantial doubt exists as to ability to continue as a going concern.
• Will need substantial additional financing to develop product candidates and implement operating plan; failure to obtain could delay, reduce, or eliminate product development or commercialization efforts.
• Limited operating history, significant net losses since inception, and anticipate continued significant net losses for the foreseeable future, expected to increase with clinical development and regulatory approvals.
• If unable to advance product candidates in clinical development, obtain regulatory approval, and ultimately commercialize, or experience significant delays, business will be materially harmed.
• Clinical trials may fail to adequately demonstrate safety and efficacy, which could prevent or delay regulatory approval and commercialization.
• Face significant competition from other biotechnology and pharmaceutical companies.
• Preclinical and clinical drug development is lengthy, expensive, with uncertain outcomes; earlier results may not be predictive.
• May incur additional costs or experience delays in completing, or ultimately be unable to complete, development and commercialization of TA-ERT, tildacerfont, SPR202 and other current and future product candidates.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Any delays in commencement or completion, or termination or suspension, of clinical trials could result in increased costs, delay or limit ability to generate revenue, and adversely affect commercial prospects.
• TA-ERT, tildacerfont, and SPR202 are subject to extensive, costly, and time-consuming regulation and compliance obligations, which may cause unanticipated delays or prevent required approvals.
• Interim, topline, and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification.
• If market opportunities for product candidates are smaller than believed, future revenue may be adversely affected.
• Currently have no marketing and sales organization and have not commercialized a product; inability to establish or partner could prevent product revenues.
• Unfavorable U.S. and global economic and geopolitical conditions could adversely affect business.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business.
• Highly dependent on key personnel; failure to attract and retain.
• Coverage and reimbursement may be limited or unavailable, making profitable sales difficult.
• Failure to develop and commercialize additional product candidates may prevent business growth.
• Depend on intellectual property licensed from others; termination could result in loss of significant rights.
• Rely on third parties to conduct clinical trials; failure to carry out duties or meet deadlines.
• Rely completely on third parties to manufacture drug supplies; failure to obtain/maintain regulatory approval for facilities, provide sufficient quantities, or at acceptable quality/prices.
• Inability to obtain and maintain sufficient intellectual property protection, or if scope is not broad enough, competitors could commercialize similar products.
• Use of TA-ERT, tildacerfont, SPR202 could be associated with side effects, adverse events, or other properties delaying/preventing approval or resulting in negative consequences post-approval.
• Ongoing regulatory obligations and continued regulatory review post-approval may result in significant additional expense and penalties for non-compliance.
• Even if regulatory approval is obtained, product candidates may not gain market acceptance.
• Improper promotion of off-label uses or off-label prescription by physicians could lead to sanctions.
• Current and future legislation and healthcare reform measures may increase difficulty and cost to obtain marketing approval and commercialize.
• Compromised information technology systems or data could lead to adverse consequences.
• Product liability lawsuits may incur substantial liabilities.
• Subject to U.S. and foreign export/import controls, sanctions, anti-corruption, and anti-money laundering laws.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited.
• Inability to maintain Nasdaq compliance could adversely affect market liquidity and price.
• Trading price of common stock has been, and may continue to be, volatile.
• Could be subject to securities class action litigation.
• If securities or industry analysts do not publish research or publish inaccurate/unfavorable research, stock price could decline.
• Do not intend to pay dividends on common stock.
• Principal stockholders and management own a significant percentage of stock and can exert significant control.
• Reduced reporting requirements as an emerging growth company and smaller reporting company may make common stock less attractive to investors.
• Obligated to develop and maintain proper and effective internal control over financial reporting; failure could adversely affect investor confidence.
• Incurred and will continue to incur significant increased costs as a public company.
• Sales of substantial number of shares could cause stock price to fall.
• Future sales and issuances of common stock or rights to purchase could result in additional dilution.
• Anti-takeover provisions could delay or prevent a change of control.
• Exclusive forum for disputes could limit stockholders' ability to obtain favorable judicial forum.
• Future collaboration arrangements may not be successful.
• Social media platforms and AI-based platforms present new risks.
• May become subject to claims challenging inventorship or ownership of patents.
• Changes in U.S. patent law could diminish the value of patents.
• May not be able to protect intellectual property rights throughout the world.
• Failure to comply with obligations in license agreements could lead to loss of rights.
• Third-party claims alleging intellectual property infringement may prevent or delay drug discovery.
• Inability to protect confidentiality of trade secrets.
• Trademarks and trade names not adequately protected could harm name recognition.

Future Outlook

Spruce Biosciences anticipates submitting a Biologics License Application (BLA) for tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B in the first quarter of 2026, with a potential commercial launch in late 2026 if approved. The company also expects topline results from the TAMARIND Phase 2 proof-of-concept clinical trial for tildacerfont in Major Depressive Disorder in the first half of 2026. Research and development expenses are projected to increase significantly as TA-ERT progresses towards regulatory approval and commercialization, and other product candidates advance through development. The company will require substantial additional capital to fund future operations and debt obligations beyond the next 12 months.

Management Comments

• "We believe that based on our current operating plan, our cash and cash equivalents of $10.7 million as of September 30, 2025 and proceeds from the October 2025 private placement financing will be insufficient to fund our planned operations and debt obligations for at least 12 months following the issuance date of these financial statements."
• "The Company's ability to continue as a going concern will require the Company to raise additional capital to fund the Company's operations and there can be no assurance that additional financing will be available to the Company or that such financing, if available, will be available on terms acceptable to the Company."
• "We anticipate submitting a biologics license application of TA-ERT for the treatment of Sanfilippo Syndrome Type B in the first quarter of 2026."
• "If successful and FDA approval is received, potentially commercially launch in late 2026."
• "Topline results from TAMARIND are anticipated in the first half of 2026."
• "We expect our expenses will increase significantly in connection with our ongoing activities."
• "We intend to build a highly specialized commercial organization to support the commercialization of TA-ERT, if approved, in the United States."

Industry Context

The biopharmaceutical industry is characterized by intense competition, rapid innovation, and significant capital requirements for drug development. Spruce Biosciences' strategic shift to focus on TA-ERT for MPS IIIB, a rare neurodegenerative pediatric disorder with no FDA-approved therapy, positions it in an orphan drug market. The FDA's Breakthrough Therapy Designation for TA-ERT is a significant positive, potentially accelerating its path to market. However, the company faces substantial liquidity challenges common for late-stage biopharmaceutical firms without commercialized products, necessitating continuous capital raises. The discontinuation of the tildacerfont CAH program reflects the high failure rate in clinical development. The broader economic and geopolitical uncertainties, including inflation and supply chain disruptions, add to the operational complexities faced by companies in this sector.

Comparison to Industry Standards

• The FDA's Breakthrough Therapy Designation for TA-ERT is a strong indicator of potential clinical benefit and unmet medical need, placing it in a favorable regulatory pathway compared to standard drug development.
• The company's accumulated deficit of $274.6 million and ongoing net losses are typical for a late-stage biopharmaceutical company that has not yet commercialized a product, as R&D is capital-intensive.
• The 55% workforce reduction and discontinuation of the tildacerfont CAH program reflect a common industry practice of prioritizing pipeline assets and conserving capital in response to clinical trial outcomes and financial constraints.
• The reliance on third-party CROs and manufacturers is standard in the biopharmaceutical industry, but also introduces risks related to quality control, supply chain, and regulatory compliance.
• The need for continuous capital raises, as evidenced by the $50 million private placement, is a common characteristic of pre-revenue biotech companies funding extensive clinical development.
• The volatility of the stock price and the Nasdaq delisting/relisting event highlight the inherent risks and scrutiny faced by smaller biopharmaceutical companies in public markets.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• The company is a party to an opposition proceeding with the European Patent Office, a Revocation Proceeding, and a Unified Patent Court (UPC) Revocation Proceeding with respect to EP Patent No. 3,678,649.

Related Party Transactions

• Michael Grey, the Executive Chairman of the Board, purchased one share of Series A Preferred Stock for $100.00 on May 28, 2025, which was redeemed for $100.00 on July 22, 2025.
• Kirk Ways, M.D., a member of the Board, began serving as interim Chief Medical Officer on December 20, 2024, under a consulting agreement, for which the company recognized $0.3 million in compensation expense during the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Experienced significant dilution from the 1-for-75 reverse stock split and the recent private placement. Face substantial risk due to the company's going concern doubt and need for further capital. Potential for significant upside if TA-ERT gains approval and commercial success.
• Employees: Affected by a 55% workforce reduction in April 2025. Remaining employees face uncertainty due to the company's financial condition but may benefit from the strategic focus on TA-ERT.
• Customers (future): Patients with Sanfilippo Syndrome Type B could benefit significantly from TA-ERT if approved, as there are currently no FDA-approved therapies.
• Creditors: The Term Loan with Silicon Valley Bank was fully prepaid and terminated, resolving that specific debt obligation.
• Partners (HBM, Lilly, Kaken): Continued collaboration and potential milestone/royalty payments depend on the successful development and commercialization of licensed product candidates.

Next Steps

• Submit a Biologics License Application (BLA) for tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B in Q1 2026.
• Potentially commercially launch TA-ERT in late 2026, if FDA approval is received.
• Initiate a confirmatory Phase 3 trial for TA-ERT (placebo-controlled 5-year study with a 2-year interim analysis in 14 patients) prior to potential accelerated approval.
• Build a highly specialized commercial organization to support TA-ERT commercialization in the United States.
• Seek strategic collaborations for TA-ERT in markets outside the United States.
• Advance TA-ERT through a planned confirmatory study and expanded access programs.
• Expand manufacturing capacity for TA-ERT.
• Anticipate topline results from the TAMARIND Phase 2 proof-of-concept clinical trial for tildacerfont in Major Depressive Disorder in H1 2026.
• Advance preclinical and clinical development of SPR202 in congenital adrenal hyperplasia (CAH).
• Implement operational, financial, and management information systems.
• Hire additional personnel.
• Obtain, maintain, expand, and protect the intellectual property portfolio.
• Raise additional capital to fund future operations and debt obligations.

Key Dates

Recommendation

Spruce Biosciences presents a high-risk, high-reward profile. The FDA Breakthrough Therapy Designation for TA-ERT in Sanfilippo Syndrome Type B is a significant positive, indicating potential for accelerated approval and addressing a critical unmet medical need. The recent $50 million capital raise provides a temporary liquidity buffer and the termination of the SVB loan reduces immediate debt pressure. However, the company still faces substantial doubt about its ability to continue as a going concern, has no product revenue, and will require significant additional financing. The prior delisting from Nasdaq and the substantial workforce reduction highlight past operational and financial struggles. While the TA-ERT program offers a compelling long-term opportunity, the near-term financial instability and the inherent risks of clinical development and commercialization warrant a 'hold' recommendation. Investors should monitor the BLA submission, confirmatory trial progress, and future financing efforts closely before considering further investment.

Keywords

Spruce Biosciences, SPRB, Biopharmaceutical, Neurological Disorders, Sanfilippo Syndrome Type B, TA-ERT, Tralesinidase Alfa, MPS IIIB, Breakthrough Therapy Designation, FDA, BLA, Tildacerfont, Major Depressive Disorder, MDD, Cortibon, TAMARIND, SPR202, Congenital Adrenal Hyperplasia, CAH, Clinical Trials, Drug Development, SEC Filing, 10-Q, Financial Results, Net Loss, Cash Position, Private Placement, Capital Raise, Going Concern, Nasdaq, Reverse Stock Split, Intellectual Property, License Agreement, HBM Alpha Therapeutics, Allievex, Eli Lilly, Kaken Pharmaceutical, Risk Factors, Biotech, Pharmaceutical